Background: Chronic heart failure (CHF) and chronic obstructive pulmonary disease (COPD) are associated with high rates of mortality in elderly subjects. Concurrent CHF and COPD frequently occur, especially in with advancing age. This study examines long-term mortality in community-dwelling elderly subjects affected by CHF alone, COPD alone, and coexistent CHF and COPD.
Methods: The study evaluated 12-years mortality in 1288 subjects stratified for the presence or absence of CHF or COPD alone, and for coexistence of CHF and COPD.
Results: Mortality, at 12 year follow-up, was 46.7% overall, 68.6% in the presence of CHF alone (p < 0.001), 56.9% in the presence of COPD alone (p < 0.01); mortality was 86.2% where CHF and COPD coexisted (p < 0.001) and was significantly higher than in CHF or COPD alone (p < 0.05). Multivariate analysis indicates that CHF (Hazard risk = 1.67, 95% confidence interval 1.15-3.27, p < 0.031) and COPD (Hazard risk = 1.27, 95% confidence interval = 1.08-1.85, p < 0.042) were predictive of long-term mortality. When CHF and COPD simultaneously occurred, the risk dramatically increased up to 3.73 (95% confidence interval = 1.19-6.93, p < 0.001).
Conclusions: Long-term follow-up showed higher mortality among elderly subjects affected by CHF or COPD. Simultaneous presence of CHF and COPD significantly increased the risk of death. Therefore, the presence of COPD in CHF patients should be considered a relevant factor in predicting high risk of mortality.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s40520-016-0720-5 | DOI Listing |
Prim Care Companion CNS Disord
January 2025
Eisai Inc, Nutley, New Jersey.
Insomnia and some insomnia treatments can impact an individual's daytime functioning. Here, we performed post hoc analyses of patient-reported outcomes from a phase 3 clinical trial to assess the impact of lemborexant (LEM), a dual orexin receptor antagonist, on daytime functioning. Adults with insomnia were randomized 1:1:1 to receive placebo, LEM 5 mg (LEM5) or LEM 10 mg (LEM10) for 6 months.
View Article and Find Full Text PDFBrain Spine
October 2024
Centre for Global Health Research, Saveetha Medical Collage and Hospitals, Saveetha Institute of Medical and Technical Sciences, Chennai, Tamil Nadu, 600077, India.
J Clin Exp Dent
December 2024
Doctor, Lecturer. Faculty of Odonto-Stomatology, University of Medicine and Pharmacy at Ho Chi Minh City, 652 Nguyen Trai Street, Ward 11, District 5, 749000, Ho Chi Minh City, Vietnam.
Background: Bite force is one of the important factors that determine the chewing efficiency of molars. This study aimed to investigate the relationship of the maximum bite force (MBF) to the 3-dimensional (3D) arrangement of the first mandibular molars in Angle's class I healthy adults using a digital protocol.
Material And Methods: Subjects were 33 adults (16 males and 17 females) aged 18-25, with Angle's class I occlusions and healthy dentitions.
Afr J Disabil
December 2024
Department of Occupational Therapy, Faculty of Medicine and Health Science, Stellenbosch University, Cape Town, South Africa.
Background: Play is integral to optimal childhood development. Occupational therapists often use play to improve play skills. However, when it comes to learners with autism spectrum disorder (ASD) in South Africa, there is limited research regarding play-based interventions that address the underlying motivators of play, namely, social play and playfulness.
View Article and Find Full Text PDFKidney Med
November 2024
Department of Medicine, University of Illinois Chicago, Chicago, IL.
Rationale & Objective: In the general population, neighborhood socioeconomic status (SES) has been found to be associated with cardiovascular risk, but this relationship has not been well studied among patients with chronic kidney disease (CKD). This study seeked to evaluate the association between neighborhood SES and cardiovascular outcomes in a CKD cohort.
Study Design: Multicenter prospective cohort.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!